Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $512.59 million. The enterprise value is $433.90 million.
Important Dates
The last earnings date was Wednesday, March 4, 2026, after market close.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 122.05 million shares outstanding. The number of shares has increased by 23.29% in one year.
| Current Share Class | 122.05M |
| Shares Outstanding | 122.05M |
| Shares Change (YoY) | +23.29% |
| Shares Change (QoQ) | +10.29% |
| Owned by Insiders (%) | 3.15% |
| Owned by Institutions (%) | 56.43% |
| Float | 111.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.51 |
| Forward PS | 7.87 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.14
| Current Ratio | 3.14 |
| Quick Ratio | 2.92 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.92% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -62.98% |
| Weighted Average Cost of Capital (WACC) | 14.42% |
| Revenue Per Employee | $303,027 |
| Profits Per Employee | -$569,959 |
| Employee Count | 147 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 3.04 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.49% in the last 52 weeks. The beta is 1.59, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +58.49% |
| 50-Day Moving Average | 4.24 |
| 200-Day Moving Average | 4.72 |
| Relative Strength Index (RSI) | 52.53 |
| Average Volume (20 Days) | 2,409,393 |
Short Selling Information
The latest short interest is 20.04 million, so 16.42% of the outstanding shares have been sold short.
| Short Interest | 20.04M |
| Short Previous Month | 20.39M |
| Short % of Shares Out | 16.42% |
| Short % of Float | 17.90% |
| Short Ratio (days to cover) | 3.00 |
Income Statement
In the last 12 months, AQST had revenue of $44.55 million and -$83.78 million in losses. Loss per share was -$0.78.
| Revenue | 44.55M |
| Gross Profit | 25.99M |
| Operating Income | -71.05M |
| Pretax Income | -83.78M |
| Net Income | -83.78M |
| EBITDA | -70.48M |
| EBIT | -71.05M |
| Loss Per Share | -$0.78 |
Full Income StatementBalance Sheet
The company has $121.17 million in cash and $42.48 million in debt, with a net cash position of $78.69 million or $0.64 per share.
| Cash & Cash Equivalents | 121.17M |
| Total Debt | 42.48M |
| Net Cash | 78.69M |
| Net Cash Per Share | $0.64 |
| Equity (Book Value) | -33.66M |
| Book Value Per Share | -0.28 |
| Working Capital | 101.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$52.43 million and capital expenditures -$562,000, giving a free cash flow of -$52.99 million.
| Operating Cash Flow | -52.43M |
| Capital Expenditures | -562,000 |
| Free Cash Flow | -52.99M |
| FCF Per Share | -$0.43 |
Full Cash Flow StatementMargins
Gross margin is 58.35%, with operating and profit margins of -159.50% and -188.09%.
| Gross Margin | 58.35% |
| Operating Margin | -159.50% |
| Pretax Margin | -188.09% |
| Profit Margin | -188.09% |
| EBITDA Margin | -158.22% |
| EBIT Margin | -159.50% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.29% |
| Shareholder Yield | -23.29% |
| Earnings Yield | -16.35% |
| FCF Yield | -10.34% |
Analyst Forecast
The average price target for AQST is $9.00, which is 114.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 114.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 42.75% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AQST has an Altman Z-Score of -2.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.92 |
| Piotroski F-Score | 2 |
